AIM ImmunoTech Inc. 2025 Annual Report: Key Highlights and Investor Insights

AIM ImmunoTech Inc. (NYSE American: AIM) has released its annual report for the fiscal year ended December 31, 2025, offering investors a comprehensive view of its financial position, operational progress, and strategic outlook. As an immuno-pharma company headquartered in Ocala, Florida, AIM ImmunoTech focuses on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders where current treatment options remain inadequate.

Key Points and Shareholder-Important Disclosures

• Core Business Focus: AIM ImmunoTech is engaged in the research and development of nucleic acids and natural interferon therapies. The company’s pipeline targets multiple cancers and chronic diseases, leveraging its strong foundation of laboratory, pre-clinical, and clinical data.
• Listing Status & Share Information: AIM ImmunoTech’s common stock trades on the NYSE American under the symbol “AIM”. As of March 25, 2026, there were 8,147,782 shares outstanding. The aggregate market value of public float as of June 30, 2025, was \$6,411,460.
• Regulatory Compliance and Reporting: The company is a non-accelerated filer and a smaller reporting company. It is not an emerging growth company and is not a shell company. AIM has filed all required SEC reports and interactive data files on time during the past 12 months.
• Financial Statement Integrity: There have been no corrections of errors or restatements in the financial statements for the period, and no recovery analysis of incentive-based compensation was required. The company has not filed a report on management’s assessment of internal control effectiveness under Section 404(b) of Sarbanes-Oxley.
• Corporate Identity and Evolution: The company was formerly known as Hemispherx Biopharma Inc. and changed its name to AIM ImmunoTech Inc. in 1995.
• Strategic Partnerships and R&D: The financials include references to research and development expenses involving partners such as Jubilant HollisterStier, Sterling Pharma Solutions, Erasmus, Azenova Sales International, and Alcami, indicating ongoing collaborations to advance the therapeutic pipeline.
• Capital Structure and Instruments: The report contains extensive disclosures on various classes of preferred stock, stock warrants, rights offerings, and share-based compensation arrangements, signaling active management of capital structure and incentives for employees and partners.
• Subsequent Events: The filing references subsequent events, including rights offerings and the issuance of new classes of convertible preferred stock and warrants. These events could impact capital structure and dilution, and may be price-sensitive for current shareholders.
• Risk Factors and Legal Proceedings: Detailed risk factors, unresolved staff comments, cybersecurity, legal proceedings, and mine safety disclosures are included in the report, which investors should review closely for potential impacts on business operations and valuation.

Potentially Price-Sensitive Items

• Ongoing and New Capital Raises: The mention of subsequent rights offerings and the creation/issuance of new classes of preferred stock and warrants after the reporting period could result in dilution of existing shares or changes to capital structure—factors that may influence share price.
• Research and Development Collaborations: The company’s continued investment in R&D through partnerships suggests a focus on pipeline advancement. Any clinical or regulatory milestones achieved (not detailed in this excerpt) could be significant for valuation.
• Low Public Float and Market Cap: With an aggregate public float value of only \$6.4 million, the stock may be subject to higher volatility and is sensitive to any material news or trading activity.

Financial and Reporting Structure

• The company’s reporting structure is typical of a smaller public biotech, with no indication of large accelerated filer status or Section 404(b) auditor attestation.
• No documents are incorporated by reference; all information is self-contained in the filing.

Table of Contents Highlights

The annual report includes the following key sections for investors:

• Business Overview (Page 3)
• Risk Factors (Page 22)
• Unresolved Staff Comments (Page 36)
• Cybersecurity (Page 36)
• Legal Proceedings (Page 37)
• Market for Common Equity (Page 39)
• Management’s Discussion and Analysis (Page 39)
• Financial Statements (Page 47)
• Executive Compensation (Page 54)
• Principal Accountant Fees and Services (Page 65)

Conclusion

Investor Takeaways:
AIM ImmunoTech Inc. remains a development-stage immuno-pharma company with a focus on novel therapies for cancer and viral diseases. The company’s financials and disclosures indicate ongoing R&D activity, active capital management, and compliance with SEC reporting standards. Shareholders should closely monitor future capital raises, R&D milestones, and any subsequent events that may affect dilution, capital structure, or strategic direction.

The low public float and market cap suggest the potential for significant share price volatility in response to news or developments. The company’s ongoing collaborations and rights offerings could be catalysts for future value creation or dilution, making it essential for investors to stay updated on subsequent company announcements.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should review the full AIM ImmunoTech Inc. annual report and consult with their own financial advisors before making investment decisions. The information is based on public filings and may not reflect the latest developments or material events occurring after the date of the report.

View AIM ImmunoTech Inc. Historical chart here